Pipeline updates for ADHD ALXA ANAC ARQL CCXI CERU CLVS CTIC GWPH INFI MGNX PGNX PTLA RDUS SCMP TRLPF TTPH VNDA VSAR XNPT

May 07, 2015 No Comments by

Latest updates to the Company Pipeline Database for May 6 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADHD 5.53 MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2b Phase 2b enrolment due to be completed 1Q 2015. Data due 2Q 2015 ADHD 5.53 MDX (Metadoxine Extended Release (MG01CI)) Adult […]

Daily News Read more

Pipeline updates for ALKS ARDX ATRS BMRN CEMP CLDX CLVS DPRX DYAX EXEL FLXN INFI NKTR TBPH XOMA

Feb 26, 2015 No Comments by

Latest updates to the Company Pipeline Database for February 24-25, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALKS 71.11 ALKS 5461 Major depressive disorder Phase 2 Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due […]

Daily News Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments by

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Daily News Read more

NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more

Updates for GALE SCMP BLRX APPA RPTP ACOR RLYP INFI HALO ARNA CLVS SGEN ICPT GILD CUR MRK CYCC CRIS ACHN

Jan 13, 2014 No Comments

Curis, Inc.(NASDAQ:CRIS) provided an update noting that Phase 2 data of everolimus for Operable Nodular BCC (basal cell carcinoma) are due 1Q 2014. Their submission to the FDA regarding the partial clinical hold of CUDC-427 is due shortly. A Phase 2 trial of Debio 0932 is due to be to initiated in 2H 2014. Galena Biopharma (Nasdaq:GALE) announced it has […]

Read more

CNDO Phase 2 trial halted. MACK data release delay. ARQL data due 1Q 2014 + pipeline updates for AVEO APPY INSV NKTR APPY CCXI BCRX OXXI ANAC AMBI TSRO INFI + SLXP SNTS TTPH news

Nov 08, 2013 No Comments

Coronado Biosciences, Inc. (NASDAQ: CNDO $1.63) announced that the Independent Data Monitoring Committee (IDMC) recommended that their Phase 2 clinical trial in Europe evaluating Trichuris suis ova (TSO) in Crohn’s disease be stopped due to lack of efficacy. AVEO Oncology (NASDAQ: AVEO $2.07) provided an update noting that data are anticipated in 2014 from the Phase 2 trial […]

Read more

NKTR misses Phase 2 endpoint. DRTX files NDA + updates for SNSS SRPT INFI EXEL ACOR AMAG NYMX

Sep 26, 2013 No Comments

Nektar Therapeutics (Nasdaq: NKTR $10.44) announced that it failed to meet the primary endpoint in its Phase 2 trial of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The company noted that the placebo did not show the expected increase in pain scores as expected. Durata Therapeutics, Inc. (Nasdaq:DRTX […]

Read more

Updates for ALNY ZGNX INSV DNDN OGXI ANAC RPTP NPSP NKTR KERX APPA SRPT THLD OPXA BCRX IMUC INFI

Aug 09, 2013 No Comments

Zogenix, Inc. (Nasdaq:ZGNX $1.52) said it continues to expect that the FDA will reach a decision regarding the Zohyrdo ER New Drug Application(NDA), during the summer of 2013. NPS Pharmaceuticals, Inc. (NASDAQ: NPSP $18.10) said that it expects to submit its Biologic License Application in 4Q 2013 for Natpara for patients with hypoparathyroidism. It also plans to initiate […]

Read more

Pipeline updates for ACHN BCRX BLRX CLVS RIGL INSM TRGT CBST INFI AEZS SCMP SGEN FURX EXEL FLML TSRX KERX ZIOP ISIS

May 08, 2013 No Comments

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) provided an update noting that interim RVR results from its Phase 2 ACH-3102 trials for the treatment of genotype 1 HCV are due in 3Q 2013 (-007 trial), followed by SVR results during 4Q 2013. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it plans to initiate a Phase 2 trial of BCX4161 in patients with hereditary angioedema, later in 2013 […]

Read more

ABIO reverse split. NRIFF receives CRL. Updates for RIGL INFI NYMX TRGT VPHM NWBO.

Mar 05, 2013 No Comments

Targacept, Inc. (NASDAQ: TRGT) announced that AstraZeneca will return all rights to the alpha4beta2 modulator TC-1734 (also known as AZD3480), which is currently in a Phase 2b clinical trial in mild to moderate Alzheimer’s disease. It will also give up the option to license any alpha7 NNR modulator that was developed by Targacept for a cognitive disorder or schizophrenia Nuvo […]

Read more

DCTH expects May Adcom meeting. EDIT – BLRX + Pipeline updates for ALNY CLVS INFI OREX FOLD ICPT

Jan 07, 2013 No Comments

BioLineRx (NASDAQ: BLRX) announced today that the results of the interim analysis of its Phase 2/3 CLARITY trial of BL-1020, for the treatment of schizophrenia, are expected during the week beginning March 18, 2013. EDIT: DMC will provide estimate of the total number of patients required in the study in order to achieve statistical significance in the Phase 2/3 data […]

Read more